Understanding history, and not repeating it. Neuroprotection for acute ischemic stroke: From review to preview

Clinical Neurology and Neurosurgery

Volumn 129, Issue , 2015, Pages 1-9

  Grupke, Stephen ^a   Hall, Jason ^a   Dobbs, Michael ^a   Bix, Gregory J ^a   Fraser, Justin F ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Acute stroke; Angiography; Brain ischemia; Drug trials; Neuroprotection

Indexed keywords

4 PHOSPHONOMETHYLPIPECOLIC ACID; 6,7 DICHLORO 5 NITRO 2,3 QUINOXALINEDIONE; CATION CHANNEL; CITICOLINE; CLOMETHIAZOLE; DISUFENTON SODIUM; ENLIMOMAB; FLUNARIZINE; GAVESTINEL; GLUTAMIC ACID; LUBELUZOLE; MAGNESIUM; NALMEFENE; NEUROPROTECTIVE AGENT; REPINOTAN; ROVELIZUMAB; TRAFERMIN; TRAXOPRODIL; FIBRINOLYTIC AGENT;

BRAIN ISCHEMIA; EXCITOTOXICITY; EXTRACELLULAR MATRIX; FOLLOW UP; HUMAN; LEUKOCYTE MIGRATION; MEDLINE; NEUROPROTECTION; NEUROTRANSMISSION; PHOSPHOLIPID MEMBRANE; REVIEW; ANIMAL; APOPTOSIS; DRUG EFFECTS; FIBRINOLYTIC THERAPY; PHYSIOLOGY; STROKE;

ANIMALS; APOPTOSIS; BRAIN ISCHEMIA; FIBRINOLYTIC AGENTS; HUMANS; NEUROPROTECTIVE AGENTS; STROKE; THROMBOLYTIC THERAPY;

EID: 84919625840     PISSN: 03038467     EISSN: 18726968     Source Type: Journal    
DOI: 10.1016/j.clineuro.2014.11.013     Document Type: Review

References (85)

1. V.L. Roger, A.S. Go, D.M. Lloyd-Jones, R.J. Adams, J.D. Berry, and T.M. Brown Heart disease and stroke statistics - 2011 update: a report from the American Heart Association Circulation 123 4 2011 e18 e209
2. B. Ovbiagele, C.S. Kidwell, and J.L. Saver Epidemiological impact in the United States of a tissue-based definition of transient ischemic attack Stroke 34 4 2003 919 924
3. A.M. Harper Physiology of cerebral blood flow Br J Anaesth 37 1965 225 235
4. B.C. White, J.M. Sullivan, D.J. DeGracia, B.J. O'Neil, R.W. Neumar, and L.I. Grossman Brain ischemia and reperfusion: molecular mechanisms of neuronal injury J Neurol Sci 179 S 1-2 2000 1 33
5. M.P. Goldberg, P.C. Pham, and D.W. Choi Dextrorphan and dextromethorphan attenuate hypoxic injury in neuronal culture Neurosci Lett 80 1 1987 11 15
6. C.P. George, M.P. Goldberg, D.W. Choi, and G.K. Steinberg Dextromethorphan reduces neocortical ischemic neuronal damage in vivo Brain Res 440 2 1988 375 379
7. G.W. Albers, R.P. Atkinson, R.E. Kelley, and D.M. Rosenbaum Safety, tolerability, and pharmacokinetics of the N-methyl-d-aspartate antagonist dextrorphan in patients with acute stroke. Dextrorphan Study Group Stroke 26 2 1995 254 258
8. S.A. Mousavi, M. Saadatnia, F. Khorvash, T. Hoseini, and P. Sariaslani Evaluation of the neuroprotective effect of dextromethorphan in the acute phase of ischaemic stroke Arch Med Sci 7 3 2011 465 469
9. L. Nowak, P. Bregestovski, P. Ascher, A. Herbet, and A. Prochiantz Magnesium gates glutamate-activated channels in mouse central neurones Nature 307 5950 1984 462 465
10. Y. Izumi, S. Roussel, E. Pinard, and J. Seylaz Reduction of infarct volume by magnesium after middle cerebral artery occlusion in rats J Cerebr Blood Flow Metab 11 6 1991 1025 1030
11. J.L. Saver, C. Kidwell, M. Eckstein, and S. Starkman Prehospital neuroprotective therapy for acute stroke: results of the Field Administration of Stroke Therapy - Magnesium (FAST-MAG) pilot trial Stroke 35 5 2004 e106 e108
12. S. Hughes FAST-MAG: No benefit of prehospital magnesium in stroke Medscape Medical News: WebMD 2014 LLC Available from: http://www.medscape.com/viewarticle/820638
13. J.L.E. Saver, M. Stratton, S. Pratt, F. Hamilton, S. Conwit, and R. Liebeskind Abstract 214: The Field Administration of Stroke Therapy - Magnesium (FAST-MAG) Phase 3 Trial: primary results Stroke 45 Suppl. 1 2014 A214
14. K.W. Muir, K.R. Lees, I. Ford, and S. Davis Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke trial): randomised controlled trial Lancet 363 9407 2004 439 445
15. A.S. Lesage, L. Peeters, and J.E. Leysen Lubeluzole, a novel long-term neuroprotectant, inhibits the glutamate-activated nitric oxide synthase pathway J Pharmacol Exp Ther 279 2 1996 759 766
16. D.K. Scheller, M. De Ryck, J. Kolb, S. Szathmary, J. van Reempts, and G. Clincke Lubeluzole blocks increases in extracellular glutamate and taurine in the peri-infarct zone in rats Eur J Pharmacol 338 3 1997 243 251
17. H.C. Diener, M. Cortens, G. Ford, J. Grotta, W. Hacke, and M. Kaste Lubeluzole in acute ischemic stroke treatment: a double-blind study with an 8-hour inclusion window comparing a 10-mg daily dose of lubeluzole with placebo Stroke 31 11 2000 2543 2551
18. K. Minematsu, M. Fisher, L. Li, M.A. Davis, A.G. Knapp, and R.E. Cotter Effects of a novel NMDA antagonist on experimental stroke rapidly and quantitatively assessed by diffusion-weighted MRI Neurology 43 2 1993 397 403
19. A.G. Dyker, K.R. Edwards, P.B. Fayad, J.T. Hormes, and K.R. Lees Safety and tolerability study of aptiganel hydrochloride in patients with an acute ischemic stroke Stroke 30 10 1999 2038 2042
20. PRNewswire Cambridge neuroscience reports preliminary analysis of CERESTAT(R) phase III data; potential benefit in stroke sub-population to be assessed 1998 Available from: http://www2.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/3-9-98/431086&EDATE=)
21. X. Di, R. Bullock, J. Watson, P. Fatouros, B. Chenard, and F. White Effect of CP101,606, a novel NR2B subunit antagonist of the N-methyl-d-aspartate receptor, on the volume of ischemic brain damage off cytotoxic brain edema after middle cerebral artery occlusion in the feline brain Stroke 28 11 1997 2244 2251
22. M.R. Bullock, R.E. Merchant, C.A. Carmack, E. Doppenberg, A.K. Shah, and K.D. Wilner An open-label study of CP-101,606 in subjects with a severe traumatic head injury or spontaneous intracerebral hemorrhage Ann N Y Acad Sci 890 1999 51 58
23. M.W. Saltarelli, J.J.C. Hsu, and M.M. Bednar Randomized double-blind, placebo-controlled study to evaluate the safety and efficacy of CP-101,606 (traxoprodil), an NR2B-selective N-methyl-d-aspartate antagonist in subjects with acute ischemic stroke Stroke 35 1 2004 1
24. M.A. Black, R. Tremblay, G.A. Mealing, J.P. Durkin, J.F. Whitfield, and P. Morley The desglycinyl metabolite of remacemide hydrochloride is neuroprotective in cultured rat cortical neurons J Neurochem 66 3 1996 989 995
25. P.E. Bannan, D.I. Graham, K.R. Lees, and J. McCulloch Neuroprotective effect of remacemide hydrochloride in focal cerebral ischemia in the cat Brain Res 664 1-2 1994 271 275
26. A.G. Dyker, and K.R. Lees Remacemide hydrochloride: a double-blind, placebo-controlled, safety and tolerability study in patients with acute ischemic stroke Stroke 30 9 1999 1796 1801
27. J.E. Arrowsmith, M.J. Harrison, S.P. Newman, J. Stygall, N. Timberlake, and W.B. Pugsley Neuroprotection of the brain during cardiopulmonary bypass: a randomized trial of remacemide during coronary artery bypass in 171 patients Stroke 29 11 1998 2357 2362
28. R. Malek, K.K. Borowicz, Z. Kimber-Trojnar, G. Sobieszek, B. Piskorska, and S.J. Czuczwar Remacemide - a novel potential antiepileptic drug Pol J Pharmacol 55 5 2003 691 698
29. Remacemide AstraZeneca discontinued, Europe, USA Canada R & D Focus Drug News 2004 IMSworld Publications Ltd Available from: http://business.highbeam.com/436989/article-1G1-114382356/remacemide-astrazeneca-discontinued-europe-usa-canada
30. R. Simon, and K. Shiraishi N-methyl-d-aspartate antagonist reduces stroke size and regional glucose metabolism Ann Neurol 27 6 1990 606 611
31. J. Grotta, W. Clark, B. Coull, L.C. Pettigrew, B. Mackay, and L.B. Goldstein Safety and tolerability of the glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischemic stroke. Results of a phase IIa randomized trial Stroke 26 4 1995 602 605
32. S.M. Davis, K.R. Lees, G.W. Albers, H.C. Diener, S. Markabi, and G. Karlsson Selfotel in acute ischemic stroke: possible neurotoxic effects of an NMDA antagonist Stroke 31 2 2000 347 354
33. D.S. Warner, H. Martin, P. Ludwig, A. McAllister, J.F. Keana, and E. Weber In vivo models of cerebral ischemia: effects of parenterally administered NMDA receptor glycine site antagonists J Cereb Blood Flow Metab 15 2 1995 188 196
34. G.W. Albers, W.M. Clark, R.P. Atkinson, K. Madden, J.L. Data, and M.J. Whitehouse Dose escalation study of the NMDA glycine-site antagonist licostinel in acute ischemic stroke Stroke 30 3 1999 508 513
35. F. Bordi, C. Pietra, L. Ziviani, and A. Reggiani The glycine antagonist GV150526 protects somatosensory evoked potentials and reduces the infarct area in the MCAo model of focal ischemia in the rat Exp Neurol 145 2 Pt. 1 1997 425 433
36. R.L. Sacco, J.T. DeRosa, E.C. Haley Jr., B. Levin, P. Ordronneau, and S.J. Phillips Glycine antagonist in neuroprotection for patients with acute stroke: GAIN Americas: a randomized controlled trial JAMA 285 13 2001 1719 1728
37. S. Warach, D. Kaufman, D. Chiu, T. Devlin, M. Luby, and A. Rashid Effect of the glycine antagonist gavestinel on cerebral infarcts in acute stroke patients, a randomized placebo-controlled trial: The GAIN MRI Substudy Cerebrovasc Dis 21 1-2 2006 106 111
38. J.W. Marshall, A.J. Cross, D.M. Jackson, A.R. Green, H.F. Baker, and R.M. Ridley Clomethiazole protects against hemineglect in a primate model of stroke Brain Res Bull 52 1 2000 21 29
39. A.J. Cross, J.A. Jones, H.A. Baldwin, and A.R. Green Neuroprotective activity of chlormethiazole following transient forebrain ischaemia in the gerbil Br J Pharmacol 104 2 1991 406 411
40. S.G. Sydserff, A.J. Cross, and A.R. Green The neuroprotective effect of chlormethiazole on ischaemic neuronal damage following permanent middle cerebral artery ischaemia in the rat Neurodegeneration 4 3 1995 323 328
41. N.G. Wahlgren, K.W. Ranasinha, T. Rosolacci, C.L. Franke, P.M. van Erven, and T. Ashwood Clomethiazole Acute Stroke Study (CLASS): results of a randomized, controlled trial of clomethiazole versus placebo in 1360 acute stroke patients Stroke 30 1 1999 21 28
42. P. Lyden, A. Shuaib, K. Ng, K. Levin, R.P. Atkinson, and A. Rajput Clomethiazole Acute Stroke Study in ischemic stroke (CLASS-I): final results Stroke 33 1 2002 122 128
43. S.H. Graham, H. Shimizu, A. Newman, P. Weinstein, and A.I. Faden Opioid receptor antagonist nalmefene stereospecifically inhibits glutamate release during global cerebral ischemia Brain Res 632 1-2 1993 346 350
44. A.I. Faden, R. Shirane, L.H. Chang, T.L. James, M. Lemke, and P.R. Weinstein Opiate-receptor antagonist improves metabolic recovery and limits neurochemical alterations associated with reperfusion after global brain ischemia in rats J Pharmacol Exp Ther 255 2 1990 451 458
45. W.M. Clark, E.C. Raps, D.C. Tong, and R.E. Kelly Cervene (Nalmefene) in acute ischemic stroke: final results of a phase III efficacy study. The Cervene Stroke Study Investigators Stroke 31 6 2000 1234 1239
46. I. Semkova, P. Wolz, and J. Krieglstein Neuroprotective effect of 5-HT1A receptor agonist, Bay X 3702, demonstrated in vitro and in vivo Eur J Pharmacol 359 2-3 1998 251 260
47. A.C. Berends, P.G. Luiten, and C. Nyakas A review of the neuroprotective properties of the 5-HT1A receptor agonist repinotan HCl (BAYx3702) in ischemic stroke CNS Drug Rev 11 4 2005 379 402
48. P. Teal, F.L. Silver, and D. Simard The BRAINS study: safety, tolerability, and dose-finding of repinotan in acute stroke Can J Neurol Sci 32 1 2005 61 67
49. P. Teal, S. Davis, W. Hacke, M. Kaste, P.D. Lyden, and M. Fierus A randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, tolerability, and pharmacokinetic/pharmacodynamic effects of a targeted exposure of intravenous repinotan in patients with acute ischemic stroke: modified Randomized Exposure Controlled Trial (mRECT) Stroke 40 11 2009 3518 3525
50. A. Bethel, J.R. Kirsch, R.C. Koehler, S.P. Finklestein, and R.J. Traystman Intravenous basic fibroblast growth factor decreases brain injury resulting from focal ischemia in cats Stroke 28 3 1997 609 615 discussion 15-16
51. N. Jiang, S.P. Finklestein, T. Do, C.G. Caday, M. Charette, and M. Chopp Delayed intravenous administration of basic fibroblast growth factor (bFGF) reduces infarct volume in a model of focal cerebral ischemia/reperfusion in the rat J Neurol Sci 139 2 1996 173 179
52. J. Bogousslavsky, S.J. Victor, E.O. Salinas, A. Pallay, G.A. Donnan, and C. Fieschi Fiblast (trafermin) in acute stroke: results of the European-Australian phase II/III safety and efficacy trial Cerebrovasc Dis 14 3-4 2002 239 251
53. A. Shuaib, Y. Yang, and Q. Li Evaluating the efficacy of citicoline in embolic ischemic stroke in rats: neuroprotective effects when used alone or in combination with urokinase Exp Neurol 161 2 2000 733 739
54. W.M. Clark, S.J. Warach, L.C. Pettigrew, R.E. Gammans, and L.A. Sabounjian A randomized dose-response trial of citicoline in acute ischemic stroke patients. Citicoline Stroke Study Group Neurology 49 3 1997 671 678
55. W.M. Clark, B.J. Williams, K.A. Selzer, R.M. Zweifler, L.A. Sabounjian, and R.E. Gammans A randomized efficacy trial of citicoline in patients with acute ischemic stroke Stroke 30 12 1999 2592 2597
56. S. Warach, L.C. Pettigrew, J.F. Dashe, P. Pullicino, D.M. Lefkowitz, and L. Sabounjian Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Citicoline 010 Investigators Ann Neurol 48 5 2000 713 722
57. W.M. Clark, L.R. Wechsler, L.A. Sabounjian, and U.E. Schwiderski A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients Neurology 57 9 2001 1595 1602
58. A. Davalos, J. Castillo, J. Alvarez-Sabin, J.J. Secades, J. Mercadal, and S. Lopez Oral citicoline in acute ischemic stroke: an individual patient data pooling analysis of clinical trials Stroke 33 12 2002 2850 2857
59. B.C. Tilley, J. Marler, N.L. Geller, M. Lu, J. Legler, and T. Brott Use of a global test for multiple outcomes in stroke trials with application to the National Institute of Neurological Disorders and Stroke t-PA Stroke Trial Stroke 27 11 1996 2136 2142
60. A. Davalos, J. Alvarez-Sabin, J. Castillo, E. Diez-Tejedor, J. Ferro, and E. Martinez-Vila Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial) Lancet 380 9839 2012 349 357
61. S. Kuroda, R. Tsuchidate, M.L. Smith, K.R. Maples, and B.K. Siesjo Neuroprotective effects of a novel nitrone, NXY-059, after transient focal cerebral ischemia in the rat J Cereb Blood Flow Metab 19 7 1999 778 787
62. K.R. Lees, J.A. Zivin, T. Ashwood, A. Davalos, S.M. Davis, and H.C. Diener NXY-059 for acute ischemic stroke N Engl J Med 354 6 2006 588 600
63. A. Shuaib, K.R. Lees, P. Lyden, J. Grotta, A. Davalos, and S.M. Davis NXY-059 for the treatment of acute ischemic stroke N Engl J Med 357 6 2007 562 571
64. H.C. Diener, K.R. Lees, P. Lyden, J. Grotta, A. Davalos, and S.M. Davis NXY-059 for the treatment of acute stroke: pooled analysis of the SAINT I and II Trials Stroke 39 6 2008 1751 1758
65. J.M. Braughler, and J.F. Pregenzer The 21-aminosteroid inhibitors of lipid peroxidation: reactions with lipid peroxyl and phenoxy radicals Free Radic Biol Med 7 2 1989 125 130
66. E.D. Hall, K.E. Pazara, and J.M. Braughler 21-Aminosteroid lipid peroxidation inhibitor U74006F protects against cerebral ischemia in gerbils Stroke 19 8 1988 997 1002
67. STIPAS Investigators Safety study of tirilazad mesylate in patients with acute ischemic stroke (STIPAS) Stroke 25 2 1994 418 423
68. Tirilazad mesylate in acute ischemic stroke: a systematic review. Tirilazad International Steering Committee Stroke 31 9 2000 2257 2265
69. W.M. Clark, K.P. Madden, R. Rothlein, and J.A. Zivin Reduction of central nervous system ischemic injury in rabbits using leukocyte adhesion antibody treatment Stroke 22 7 1991 877 883
70. D. Schneider, J. Berrouschot, T. Brandt, W. Hacke, A. Ferbert, and S.H. Norris Safety, pharmacokinetics and biological activity of enlimomab (anti-ICAM-1 antibody): an open-label, dose escalation study in patients hospitalized for acute stroke Eur Neurol 40 2 1998 78 83
71. Enlimomab Acute Stroke Trial Use of anti-ICAM-1 therapy in ischemic stroke: results of the Enlimomab Acute Stroke Trial Neurology 57 8 2001 1428 1434
72. P. Rhee, J. Morris, R. Durham, C. Hauser, M. Cipolle, and R. Wilson Recombinant humanized monoclonal antibody against CD18 (rhuMAb CD18) in traumatic hemorrhagic shock: results of a phase II clinical trial. Traumatic Shock Group J Trauma 49 4 2000 611 619 discussion 9-20
73. M.A. Yenari, D. Kunis, G.H. Sun, D. Onley, L. Watson, and S. Turner Hu23F2G, an antibody recognizing the leukocyte CD11/CD18 integrin, reduces injury in a rabbit model of transient focal cerebral ischemia Exp Neurol 153 2 1998 223 233
74. Icos halts stroke-drug study after late results disappoint. The Seattle Times. 2000 4/21/2000;Sect. Business Briefs.
75. F.S. Silverstein, K. Buchanan, C. Hudson, and M.V. Johnston Flunarizine limits hypoxia-ischemia-induced morphologic injury in immature rat brain Stroke 17 3 1986 477 482
76. M. Limburg, and A. Hijdra Flunarizine in acute ischemic stroke: a pilot study Eur Neurol 30 3 1990 121 122
77. C.L. Franke, R. Palm, M. Dalby, H.C. Schoonderwaldt, L. Hantson, and B. Eriksson Flunarizine in stroke treatment (FIST): a double-blind, placebo-controlled trial in Scandinavia and the Netherlands Acta Neurol Scand 93 1 1996 56 60
78. J.M. Simard, M. Chen, K.V. Tarasov, S. Bhatta, S. Ivanova, and L. Melnitchenko Newly expressed SUR1-regulated NC(Ca-ATP) channel mediates cerebral edema after ischemic stroke Nat Med 12 4 2006 433 440
79. H. Kunte, S. Schmidt, M. Eliasziw, G.J. del Zoppo, J.M. Simard, and F. Masuhr Sulfonylureas improve outcome in patients with type 2 diabetes and acute ischemic stroke Stroke 38 9 2007 2526 2530
80. K.N. Sheth, W.T. Kimberly, J.J. Elm, T.A. Kent, P. Mandava, and A.J. Yoo Pilot study of intravenous glyburide in patients with a large ischemic stroke Stroke 45 1 2014 281 283
81. R. Brouns, and P.P. De Deyn The complexity of neurobiological processes in acute ischemic stroke Clin Neurol Neurosurg 111 6 2009 483 495
82. G.W. Albers, L.B. Goldstein, D.C. Hess, L.R. Wechsler, K.L. Furie, and P.B. Gorelick Stroke Treatment Academic Industry Roundtable (STAIR) recommendations for maximizing the use of intravenous thrombolytics and expanding treatment options with intra-arterial and neuroprotective therapies Stroke 42 9 2011 2645 2650
83. M. Fisher, D.F. Hanley, G. Howard, E.C. Jauch, and S. Warach Recommendations from the STAIR V meeting on acute stroke trials, technology and outcomes Stroke 38 2 2007 245 248
84. G. Orive, E. Anitua, J.L. Pedraz, and D.F. Emerich Biomaterials for promoting brain protection, repair and regeneration Nat Rev Neurosci 10 9 2009 682 692
85. Multicentre Preclinical Animal Research Team. 2014; Available from: http://www.dcn.ed.ac.uk/multipart/.